Company / Cost of Revenue
Vivos Therapeutics, Inc. Cost of Revenue History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$6.0M
FY2025
5-year range
$100.0K / $6.0M
FY2021-FY2025
Trend
+8.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Increased from $200,000 to $6M over the past 2 years.
Based on SEC 10-K filings.
$6M in FY2025 with a 3-year CAGR of +146.8%.
Increased from $200,000 to $6M over the past 2 years.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +146.8%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +146.8%, indicating consistent growth.
- In FY2025, cost of revenue increased 8.7% year-over-year.
- Lowest cost of revenue in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.20 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $6.0M | +8.7% |
| FY2024 | $5.5M | +2665.0% |
| FY2023 | $200.0K | -50.0% |
| FY2022 | $400.0K | +300.0% |
| FY2021 | $100.0K | - |
| FY2020 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026